NCT07170319

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After Multiple Ascending Doses in Participants With Overweight or Obesity

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 79 (actual)
• Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	IBI3032	IBI3032. Method of administration: oral, fasted administration.
DRUG	placebo	Placebo (without active ingredients). Method of administration: oral, fasted administration.

Timeline

• Start date: 2025-09-25
• Primary completion: 2025-12-24
• Completion: 2026-03-31
• First posted: 2025-09-12
• Last updated: 2025-12-31

Locations

1 site across 1 country: China